Prevention of exercise-induced asthma by a fixed combination of disodium cromoglycate plus reproterol compared with montelukast in young patients

Arzneimittel-Forschung/Drug Research

Volumn 58, Issue 6, 2008, Pages 303-309

  Lecheler, Josef ^a   Pfannebecker, Bernhard ^a   Nguyen, Duc Tung ^b   Petzold, Ursula ^b   Munzel, Ullrich ^b   Kremer, Hans Joachim ^c,d   Maus, Joachim ^b  

^a Asthma Zentrum Buchenhöhe   (Germany)

^b MEDA Pharma GmbH and Co KG   (Germany)

^c Medical Writing Service   (Germany)

^d NONE   (Germany)

Author keywords

Antiasthmatic drugs; CAS 158966 92 8; CAS 16110 51 3; CAS 54063 54 6; Children; Disodium cromoglycate; Exercise induced asthma; Montelukast; Reproterol

Indexed keywords

ANTIASTHMATIC AGENT; CROMOGLYCATE DISODIUM PLUS REPROTEROL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST;

ADOLESCENT; ADULT; AIRWAY OBSTRUCTION; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; EXERCISE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; PRESCHOOL CHILD; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SCHOOL CHILD; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; TREADMILL;

EID: 46949109165     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296511     Document Type: Article

References (25)

1. GINA/Global initiative for asthma. GINA report: Global strategy for asthma management and prevention. National Institutes of Health, National Heart, Lung, and Blood Institute. Update 2007. www.ginasthma.org
2. Spooner CH, Spooner GR, Rowe BH. Mast-cell stabilising agents to prevent exercise-induced bronchoconstriction (Cochrane Review). In: The Cochrane Library, Issue 1, 2006. Oxford: Update Software.
3. Anderson SD. Single-dose agents in the prevention of exercise-induced asthma: a descriptive review. Treat Respir Med. 2004;3:365-379.
4. Kelly KD, Spooner CH, Rowe BH. Nedocromil sodium versus sodium cromoglycate in treatment of exercise-induced bronchoconstriction: a systematic review. Bur Respir J. 2001;17:39-45.
5. Fischer H. Ergebnisse einer multizentrischen offenen Prüfung mit einer fixen Kombination aus Dinatrium cromogli-cicum und Reproterol an 1872 Patienten. Pharmakotherapie. 1984;7:67-73.
6. Gulyas A. Doppelblindstudie zur therapeutischen Wirk-samkeit von Reproterolhydrochlorid allein und einer Kombination aus Cromoglicinsäure, Dinatriumsalz und Reproterolhydrochlorid. Pharmakotherapie. 1984;7:51-59.
7. Siemon G, Engel T, Petro W. Intraindividuelle, randomi-sierte, placebokontrollierte Vergleichsstudie zur broncho-dilatatorischen Wirkung des Beta-2-Sympathomimetikums Reproterol und einer {Combination aus Cromoglicinsäure, Dinatriumsalz und Reproterol. Pharmakotherapie. 1984;7:18-22.
8. Svenonius E, Arborelius M, Wiberg R, Ekberg P. Prevention of exercise-induced asthma by drugs inhaled from metered aerosols. Allergy. 1988;43:252-257.
9. Debelic M, Hertel G, König J. Double-blind crossover study comparing sodium cromoglycate, reproterol, reproterol plus sodium cromoglycate, and placebo in exercise-induced asthma. Ann Allergy. 1988;61:25-29.
10. Von Berg A, Albrecht B, Darlath W, Voß HW, Berdel D. Intraindividuelle, randomisierte Doppelblindstudie zum Vergleich des protektiven Effektes zwischen verschiedenen Anwendungsformen von DNCG und reproterol bei Kindern mit Anstrengungsasthma. Allergologie. 2002;11:557-564.
11. Leff JA, Busse WW, Pearlman D, Bronsky EA, Kemp J, Hendeles L, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med. 1998;339:147-152.
12. Steinshamn S, Sandsund M, Sue-Chu M, Bjermer L. Effects of montelukast and salmeterol on physical performance and exercise economy in adult asthmatics with exercise-induced bronchoconstriction. Chest 2004;126:1154-1160.
13. Storms WW, Chervinsky P, Ghannam AF, Bird S, Hustad CM, Edelman JM. Challenge-Rescue Study Group. A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. Respir Med. 2004;98:1051-1062.
14. Brooks EG, Hayden ML. Exercise-induced asthma. Nurs Clin North Am. 2003;38:689-696.
15. Tan RA, Spector SL. Exercise-induced asthma: Diagnosis and management. Ann Allergy Asthma Immunol. 2002;89:226-235.
16. Storms WW. Review of exercise-induced asthma. Med Sci Sprts Exerc. 2003;35:1464-1470.
17. Massie J. Exercise-induced asthma in children. Paediatr Drugs. 2002;4:267-278.
18. Netzer N, Steinacker JM, Schuell K, Elser A, Voß HW, Darlath W. Protective effect of oral montelukast and a fixed drug combination of inhaled sodium cromoglycate and reproterol on exercise induced asthma. ATS Int. Conference 2000, Toronto, Canada.
19. Philip G, Villaran C, Pearlman DS, Loeys T, Dass SB, Reiss TF. Protection against exercise-induced bronchoconstriction two hours after a single oral dose of montelukast. J Asthma. 2007;44:213-217.
20. Summary of product characteristics (Fachinformation): Singulair®. MSD J Dieckmann Arzneimittel, Germany. Status August 2005. www.fachinfo.de
21. Zhao JJ, Rogers JD, Holland SD, Larson P, Amin RD, Haesen R, et al. Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers. Biopharm Drug Dispos. 1997;18:769-777.
22. Richter K, Janicki S, Jorres RA, Magnussen H. Acute protection against exercise-induced bronchoconstriction by for-moterol, salmeterol and terbutaline. Eur Respir J. 2002;19:865-871.
23. Grønnerød TA, von Berg A, Schwabe G, Soliman S. Formoterol via Turbuhaler gave better protection than terbutaline against repeated exercise challenge for up to 12 hours in children and adolescents. Respir Med. 2000;94:661-667.
24. Woolley M, Anderson SD, Quigley BM. Duration of protective effect of terbutaline sulfate and cromolyn sodium alone and in combination on exercise-induced asthma. Chest. 1990;97:39-45.
25. Clarke PS, Ratowsky DA. Effect of fenoterol hydrobromide and sodium cromoglycate individually and in combination on postexercise asthma. Ann Allergy 1990;64:187-190.